European Nuclear Medicine Guide
1. Giammarile F, Bodei L, Chiesa C, Flux G, Forrer F, Kraeber-Bodere F, et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2011;38:1393–406. https://doi.org/10.1007/s00259-011-1812-2.
2. Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. International Journal of Radiation Oncology*Biology*Physics 2011;79:163–171. https://doi.org/10.1016/j.ijrobp.2009.10.062.
3. Chiesa C, Mira M, Maccauro M, Spreafico C, Romito R, Morosi C, et al. Radioembolization of hepatocarcinoma with 90Y glass microspheres: development of an individualized treatment planning strategy based on dosimetry and radiobiology. European Journal of Nuclear Medicine and Molecular Imaging 2015;42:1718–1738. https://doi.org/10.1007/s00259-015-3068-8.
4. Garin E, Lenoir L, Edeline J, Laffont S, Mesbah H, Porée P, et al. Boosted selective internal radiation therapy with 90Y-loaded glass microspheres (B-SIRT) for hepatocellular carcinoma patients: a new personalized promising concept. European Journal of Nuclear Medicine and Molecular Imaging 2013;40:1057–1068. 10.1007/s00259-013-2395-x
5. Strigari L, Sciuto R, Rea S, Carpanese L, Pizzi G, Soriani A, et al. Efficacy and Toxicity Related to Treatment of Hepatocellular Carcinoma with 90Y-SIR Spheres: Radiobiologic Considerations. Journal of Nuclear Medicine 2010;51:1377–1385. https://doi.org/10.2967/jnumed.110.075861.
6. Flamen P, Vanderlinden B, Delatte P, Ghanem G, Ameye L, Van Den Eynde M, et al. Corrigendum: Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres (2008 Phys. Med. Biol. 53 6591–603). Physics in Medicine and Biology 2014;59:2549–2551. https://doi.org/10.1088/0031-9155/59/10/2549.
7. van den Hoven AF, Rosenbaum CENM, Elias SG, de Jong HWAM, Koopman M, Verkooijen HM, et al. Insights into the Dose-Response Relationship of Radioembolization with Resin 90Y-Microspheres: A Prospective Cohort Study in Patients with Colorectal Cancer Liver Metastases. Journal of Nuclear Medicine 2016;57:1014–1019. https://doi.org/10.2967/jnumed.115.166942.
8. Manceau V, Palard X, Rolland Y, Pracht M, Le Sourd S, Laffont S, et al. A MAA-based dosimetric study in patients with intrahepatic cholangiocarcinoma treated with a combination of chemotherapy and 90Y-loaded glass microsphere selective internal radiation therapy. Eur J Nucl Med Mol Imaging 2018;45:1731–41. https://doi.org/10.1007/s00259-018-3990-7.
9. Lau WY, Leung WT, Ho S, Leung NW, Chan M, Lin J, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994;70:994–9. https://doi.org/10.1038/bjc.1994.436.
10. Garin E, Tzelikas L, Guiu B, Chalaye J, Edeline J, De Baere T, et al. Major impact of personalized dosimetry using 90Y loaded glass microspheres SIRT in HCC: Final overall survival analysis of a multicenter randomized phase II study (DOSISPHERE-01). JCO 2020;38:516–516. https://doi.org/10.1200/JCO.2020.38.4_suppl.516.
11. Levillain H, Duran Derijckere I, Ameye L, Guiot T, Braat A, Meyer C, et al. Personalised radioembolization improves outcomes in refractory intra-hepatic cholangiocarcinoma: a multicenter study. Eur J Nucl Med Mol Imaging 2019;46:2270–9. https://doi.org/10.1007/s00259-019-04427-z.
12. Gnesin S, Canetti L, Adib S, Cherbuin N, Silva Monteiro M, Bize P, et al. Partition Model-Based 99mTc-MAA SPECT/CT Predictive Dosimetry Compared with 90Y TOF PET/CT Posttreatment Dosimetry in Radioembolization of Hepatocellular Carcinoma: A Quantitative Agreement Comparison. Journal of Nuclear Medicine 2016;57:1672–1678. https://doi.org/10.2967/jnumed.116.173104.
13. Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: Biological lessons, current challenges, and clinical perspectives. Hepatology 2013;58:2188–2197. https://doi.org/10.1002/hep.26382.
14. Rosenbaum CENM, Verkooijen HM, Lam MGEH, Smits MLJ, Koopman M, van Seeters T, et al. Radioembolization for Treatment of Salvage Patients with Colorectal Cancer Liver Metastases: A Systematic Review. Journal of Nuclear Medicine 2013;54:1890–1895. https://doi.org/10.2967/jnumed.113.119545.
15. Cremonesi M, Chiesa C, Strigari L, Ferrari M, Botta F, Guerriero F, et al. Radioembolization of Hepatic Lesions from a Radiobiology and Dosimetric Perspective. Frontiers in Oncology 2014;4:210. https://doi.org/10.3389/fonc.2014.00210.
16. Monsieurs MA, Bacher K, Brans B, Vral A, Ridder L, Dierckx RA, et al. Patient dosimetry for 131I-lipiodol therapy. European Journal of Nuclear Medicine and Molecular Imaging 2003;30:554–561. https://doi.org/10.1007/s00259-002-1108-7.
17. Smits, M.L.J., Nijsen, J.F.W., van den Bosch, M.A., Lam, M.G., Vente, M.A., Mali, W.P., van het Schip, A.D., & Zonnenberg, B.A. (2012). Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): A phase 1, dose-escalation study. Lancet Oncol, 13(10), 1025–1034. https://doi.org/10.1016/S1470-2045(12)70334-0
18. Smits MLJ, Elschot M, Bosch MAAJ Van Den, Maat GH Van De, Schip AD Van Het, Zonnenberg BA, et al. In vivo dosimetry based on SPECT and MR imaging of 166Ho- microspheres for treatment of liver malignancies. Journal of Nuclear Medicine. 2013;54(12):2093–2100. 10.2967/jnumed.113.119768
19. Reinders, M.T.M., van Erpecum, K.J., Smits, M.L.J., Braat, A.J.A.T., de Bruijne, J., Bruijnen, R.C.G., Sprengers, D., de Man, R.A., Vegt, E., IJzermans, J.N.M., et al. (2022). Safety and Efficacy of Holmium-166 Radioembolization in Hepatocellular Carcinoma – The HEPAR Primary Study. J Nucl Med, 63(12), 1891–1898. https://doi.org/10.2967/jnumed.122.263823
20. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of Hepatology. 2022;76(3):681–693. 10.1016/j.jhep.2021.11.018
21. Braat AJATAT, Bruijnen RCGG, van Rooij R, Braat MNGJA, Wessels FJ, van Leeuwaarde RS, et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. The Lancet Oncology. 2020;21(4):561–570. https://doi.org/10.1016/S1470-2045(20)30027-9
22. Maat GH Van De, Seevinck PR, Elschot M, Smits MLJJ, Leeuw H De, Schip AD Van Het, et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. European Radiology. 2013;23(3):827–835. https://doi.org/10.1007/s00330-012-2648-2
23. Bastiaannet R, van Roekel C, Smits MLJ, Elias SG, van Amsterdam WAC, Doan D, et al. First evidence for a dose-Response relationship in patients treated with 166Ho radioembolization: A prospective study. Journal of Nuclear Medicine. 2020;61(4):608–612. https://doi.org/10.2967/jnumed.119.232751
24. Prince JF, Bosch MAAJ Van Den, Nijsen JFWW, Smits MLJJ, Hoven AF Van Den, Nikolakopoulos S, et al. Efficacy of radioembolization with 166Ho-Microspheres in salvage patients with liver metastases: A phase 2 study. Journal of Nuclear Medicine. 2018;59(4):582–588. https://doi.org/10.2967/jnumed.117.197194